SCHMITT DANIEL M purchased $50K of ACTU

SCHMITT DANIEL M (President, CEO and Director) purchased 140,844 shares of ACTUATE THERAPEUTICS, INC. (ACTU) at $0.36 on 2026-10-28.

Original reporting
SEC EDGAR · SCHMITT DANIEL M
Published Oct 29, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACTU
Bullish
medium confidence
Mentioned
$ACTU
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACTUBullishLow
01

Why it matters

The filing provides fresh insight into insider sentiment, which can be a factor in short-term price movement.

02

Market read

A modest insider purchase may generate slight positive bias but is unlikely to drive major price moves.

03

What to watch

The low transaction size relative to market cap may limit price impact.

Relevance 4/10Novelty 7/10Timing: after-hours filing

Background

Actuate Therapeutics filed a Form 4 reporting an insider purchase by its CEO.

Company-level read

Ticker impact

$ACTUBullishMedium confidence
Context

Form 4 shows CEO Daniel Schmitt purchased 140,844 shares for $49,999, increasing his stake to 442,560 shares.

Expected impact

potential modest upside as market prices in insider confidence

Evidence & confidence

The purchase is modest in dollar terms but represents a sizable increase in ownership by the CEO, which may be viewed favorably by investors.

Market effects

Limited impact on the broader biotech sector.

No significant regional effect.

Minimal global relevance.

Counterpoint

The purchase may be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Daniel Schmitt

    President, CEO and Director of Actuate Therapeutics

  • Actuate Therapeutics, Inc.

    Biotech firm listed on US exchanges under ticker ACTU

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACTUMed

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.